

CHI Memorial

Tocilizumab (Actemra) Use Criteria

Approved 2/10/2021; updated 3/29/2021; updated 5/31/2021; updated 8/18/2021

- COVID-19+
- Within 72 hours of supplemental oxygen requirement
- Patient rapidly decompensating within the past 24 hours
 - Rapidly increasing O2 requirements
 - Progressive pulmonary infiltrates over the past 24 hrs on chest x-ray
- Tocilizumab must be initiated within 24 hours of initiation of high flow nasal cannula, non-invasive ventilation
- C- reactive protein level must be ≥ 75 mcg/ml
- Patient must be receiving corticosteroids unless contraindicated
- Exclusions:
 - Mechanical ventilation/ECMO
 - AST/ALT $>5x$ ULN
 - Neutropenia (ANC <500 cells/ μ L)
 - Thrombocytopenia (platelet count $<50,000$ cells/ μ L)
 - Serious non-COVID-19 infection (ex: bacterial, fungal, TB etc.)
 - Treatment with a biologic immunomodulating drug in past 30 days (including baricitinib)
 - High risk for gastrointestinal perforation

Dose = 8 mg/kg IV dose (max 800 mg); single dose. Do not repeat dose.